World's Best Scientists 2026 revealed!
Véronique Leblond

Véronique Leblond

D-Index & Metrics

Medicine

D-Index
87
Citations
26732
World Ranking
13688
National Ranking
439

Véronique Leblond publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Véronique Leblond sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 548 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Véronique Leblond D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Véronique Leblond sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Véronique Leblond is affiliated with Sorbonne University in France and has contributed extensively to the field of medicine, with a specific focus on hematology and oncology. Their research portfolio includes a significant number of publications addressing aspects of lymphoma, leukemia, immunology, and molecular genetics.

Their recent research work features several key papers, including:

  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study (2020) in Blood
  • Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia (2020) in The Lancet Haematology
  • Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study (2021) in Journal of Clinical Oncology
  • Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study (2023) in Journal of Clinical Oncology
  • Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial (2020) in Blood Advances

Their frequent co-authors include Damien Roos-Weil, Christian Buske, Meletios Α. Dimopoulos, Alessandra Tedeschi, and Caroline Dartigeas.

Véronique Leblond has published mostly in:

  • Blood
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia
  • Haematologica

The main field of study is Medicine, with subfields that include:

  • Genetics
  • Pathology and Forensic Medicine
  • Immunology
  • Oncology
  • Hematology

Their research covers topics such as:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Chronic Myeloid Leukemia Treatments
  • Gastrointestinal Tumor Research and Treatment
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment

Best Publications

  • High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

    Jean-Paul Fermand;Philippe Ravaud;Sylvie Chevret;Marine Divine

  • Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

    Caroline Charlier;Élodie Perrodeau;Alexandre Leclercq;Alexandre Leclercq;Benoît Cazenave

  • High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

    Arnaud Jaccard;Philippe Moreau;Véronique Leblond;Xavier Leleu

  • High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe

    Jean-Paul Fermand;Sandrine Katsahian;Marine Divine;Veronique Leblond

  • Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

    Sylvain Choquet;Veronique Leblond;Raoul Herbrecht;Gérard Socié

  • Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.

    Enric Carreras;Hartmut Bertz;William Arcese;Jean-Paul Vernant

  • Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

    Karim Belhadj;Felix Reyes;Jean-Pierre Farcet;Herve Tilly

  • International prognostic scoring system for Waldenstrom macroglobulinemia

    Pierre Morel;Alain Duhamel;Paolo Gobbi;Meletios A. Dimopoulos

  • Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

    Ralf Trappe;Stephan Oertel;Veronique Leblond;Peter Mollee

  • Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

    N. Milpied;B. Vasseur;N. Parquet;J. L. Garnier

  • Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

    Robert A. Kyle;Steven P. Treon;Raymond Alexanian;Bart Barlogie

  • Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias.

    D. Maraninchi;D. Blaise;B. Rio;V. Leblond

  • Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma

    Hongtao Ye;Hongxiang Liu;Ayoma Attygalle;Andrew C. Wotherspoon

  • Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

    Carole Soussain;Khê Hoang-Xuan;Luc Taillandier;Emmanuelle Fourme

  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

    Constantine S. Tam;Stephen Opat;Shirley D'Sa;Wojciech Jurczak

  • Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma

    Carole Soussain;Florence Suzan;Khê Hoang-Xuan;Nathalie Cassoux

  • Anti–B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome

    Malika Benkerrou;Jean-Philippe Jais;Véronique Leblond;Anne Durandy

  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

    Meletios A. Dimopoulos;Alessandra Tedeschi;Judith Trotman;Ramón García-Sanz

  • Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

    Philippe Moreau;Véronique Leblond;Priscille Bourquelot;Thierry Facon

  • Post-transplant lymphoproliferative disorders

    Vikas R Dharnidharka;Angela C Webster;Olivia M Martinez;Jutta K Preiksaitis

Frequent Co-Authors

Frederic Davi
Frederic Davi Assistance Publique – Hôpitaux de Paris
Steven P. Treon
Steven P. Treon Harvard University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Christian Buske
Christian Buske University of Ulm
Stephan Stilgenbauer
Stephan Stilgenbauer University of Ulm
Frédéric Charlotte
Frédéric Charlotte Université Paris Cité
Ramón García-Sanz
Ramón García-Sanz University of Salamanca
Sylvie Chevret
Sylvie Chevret Université Paris Cité
Efstathios Kastritis
Efstathios Kastritis National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a wide range of online degrees and certifications, providing flexible pathways for those interested in healthcare careers. For students not ready to commit to full medical school, an accessible entry point is a medical coding certification. These programs can quickly prepare you for roles in administrative healthcare, with the potential for career growth.

Aspiring nurses can also find affordable options. For example, cheap online fnp programs allow registered nurses to advance their qualifications and become Family Nurse Practitioners without compromising their work schedules. Those just starting their nursing journey can consider online nursing school as a flexible and budget-friendly way to earn their degree and enter the healthcare workforce.

For professionals aiming to contribute to nursing education and research, doctorate in nursing education online programs provide a flexible, advanced pathway to leadership roles. These online opportunities make it easier than ever to join the medical field or advance your career while balancing other commitments.

Best Scientists Citing Véronique Leblond

Trending Scientists

Recently Published Articles